Table 3.
Patient Category | Proven CMV Disease | Probable CMV Disease | Possible CMV Disease |
---|---|---|---|
Allogeneic HCT patients | Upper and/or lower GI symptoms plus macroscopic mucosal lesions plus CMV documented in tissuea | Upper and/or lower GI symptoms and CMV documented in tissuea (not by PCR) but without the requirement for macroscopic mucosal lesions | Upper and/or lower GI symptoms and CMV documented in tissue by PCR but without the requirement for macroscopic mucosal lesions; |
Solid organ transplant patients except small bowel transplant patients | Upper and/or lower GI symptoms plus macroscopic mucosal lesions plus CMV documented in tissuea | Upper and/or lower GI symptoms and CMV documented in tissue (not by PCR) but without the requirement for macroscopic mucosal lesions | diarrhea rated at least National Cancer Institute, Common Terminology Criteria for Adverse Events (version 4.0), grade 2 and CMV documented in blood and exclusion of other likely causes of diarrhea |
Small bowel transplant patients | Upper and/or lower GI symptoms plus macroscopic mucosal lesions plus CMV documented in tissuea | Not applicable | |
Autologous HCT and CAR T cell–treated patients | Upper and/or lower GI symptoms plus macroscopic mucosal lesions plus CMV documented in tissuea | Upper and/or lower GI symptoms and CMV documented in tissue (not by PCR) but without the requirement for macroscopic mucosal lesions |
Abbreviations: CAR, Chimeric Antigen Receptor; CMV, cytomegalovirus; GI, gastrointestinal; HCT, hematopoietic cell transplant; PCR, polymerase chain reaction.
aQuantitative PCR is not accepted as a diagnostic criterion for proven or probable CMV GI disease.